Navigation Links
Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
Date:5/18/2010

ed's progress and am impressed with the significant advances that the company has made in developing its novel oral insulin capsule, ORMD-0801," said Dr. Berelowitz. "I am very pleased to join Oramed's Board of Directors and look forward to working with the leadership team to enhance the development of therapeutic applications of the company's oral drug delivery technology and in the further maturation of ORMD-0801."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, t
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
2. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
3. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
5. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
10. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
11. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... Culture Market 2014-2018" report to their offering.  ... culture is the in vitro growth of plant or ... studies, and biopharmaceutical production. Cell culture is a crucial ... instruments and cell culture consumables are necessary for the ...
(Date:7/24/2014)...  CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical ... for the prevention and treatment of cardiorenal and ... July 18, 2014 from the NYSE MKT LLC ... plan to regain compliance with continued listing standards ... is continuing the Company,s listing and has granted ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Schering-Plough Assumes Exclusive Worldwide Marketing Rights for ... N.J., May 19 Schering-Plough Corporation (NYSE: ... to its global collaboration with Novartis for ... therapies for the treatment of asthma and ...
... May 18 Solvay Pharmaceuticals announces it ... a company specialized in enabling and accelerating global ... China. Through this agreement, Solvay Pharmaceuticals will gain ... specifically on compounds in the cardiovascular area. ...
... Entire ALS Community to Join a Nationwide Network of ... ALS Therapy Development Institute (ALS TDI) announced its ... designed to increase the awareness and understanding of ALS ... To accomplish its goal, the campaign brings together three ...
Cached Biology Technology:Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 2Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China 3Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 2Campaign to Increase the Awareness and Understanding of Lou Gehrig's Disease Reaches 22 U.S. States 3
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... are elementary building blocks of life. They often perform ... to fold into three-dimensional structures. Misfolding of proteins leads ... strategies did nature develop over the course of evolution ... chemist Dr. Frauke Grter (Heidelberg Institute for Theoretical Studies) ...
... January 31, 2013 -- Deborah E. Wiley, Chair of ... JWa & JWb), announced today that the twelfth annual ... Dr. Michael Young, Rockefeller University, Dr. Jeffrey Hall, Brandeis ... The Wiley Prize is being awarded to Dr. Young, ...
... N.C. In the last decade, a new strain of ... everyone at risk of contracting the dangerous bacterial infection. This ... a chunk of genes not shared by any other strains, ... the bacteria to survive and persist in the community. ...
Cached Biology News:Protein origami: Quick folders are the best 2Protein origami: Quick folders are the best 312th annual Wiley Prize in Biomedical Sciences awarded 212th annual Wiley Prize in Biomedical Sciences awarded 3UNC study may lead to treatments that are effective against all MRSA strains 2
... ShortCut RNase III, used with its manganese-containing ... a heterogeneous mix of short (1825 bp) ... in mammalian cells. 1.3 units (1 l) ... convert 1 g of dsRNA into siRNA ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
Biology Products: